KACTUS

KACTUS

Design and manufacturing recombinant proteins: antigens for antibody drug discovery, MHC complexes, and GMP enzymes.

Founded 2018

Waltham, United States 18 employees Series B Total: $194.35M Biotechnology, Health Care

Kactus Biosystems is a pioneering biotechnology company dedicated to shaping the future of biotechnology with its bespoke protein solutions. Founded in 2018, the company specializes in designing and manufacturing high-quality and bioactive recombinant proteins for various therapeutic technologies including cell therapies, gene editing, immunotechnology, and vaccines. Kactus Biosystems stands out for its approach, where they test the configurations of proteins in different expression systems, and create 3D models to optimize protein folding, maximize bioactivity, and improve stability. The company's focus on customization and tailored solutions offers limitless potential for innovation. The latest achievement for Kactus Biosystems is the significant CNY190.00M Series B investment secured on 19 October 2022, with the backing of New Alliance Capital and Blue Bay Ventures. This investment establishes the company's position as an attractive opportunity in the biotechnology and healthcare industries. Kactus Biosystems' commitment to pushing the boundaries of biotechnology and delivering tailored solutions for transformative innovation makes it a compelling prospect for venture capital investment.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	CNY190.00M	2	New Alliance Capital, Blue Bay Ventures	19 Oct 2022
Seed Round	$4.35M	1	Divine Capital	21 Dec 2018

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

CNY190.00M

New Alliance Capital, Blue Bay Ventures

19 Oct 2022

Seed Round

$4.35M

Divine Capital

21 Dec 2018

FAQ About KACTUS

Design and manufacturing recombinant proteins: antigens for antibody drug discovery, MHC complexes, and GMP enzymes.

KACTUS was founded in 2018.

KACTUS is headquartered in Waltham, United States.

KACTUS operates in Biotechnology and Health Care. Its work centres on recombinant proteins, therapeutic technologies, cell therapies and gene editing.

KACTUS has approximately 18 employees.

KACTUS has completed 2 funding rounds, raising a total of $194.35M. The latest funding stage is Series B.

Top alternatives and competitors to KACTUS include Akron Bio, Wuhan Healthgen Biotechnology Corp., 神州细胞工程有限公司, Vectron Biosolutions AS, InVivo BioTech Services GmbH - a Bruker Company. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

KACTUS and Akron Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About KACTUS

Funding Rounds & Investors (2)

KACTUS Alternatives & Competitors

FAQ About KACTUS